Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP7 | P09237 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161761 | 1.00 | ACE (0.38) | ACEPIN1MMP2MMP7MMP9 | |
| SCHEMBL15832825 | 1.00 | ACE (0.38) | ACEPIN1MMP2MMP7MMP9 | |
| SCHEMBL30572052 | 0.88 | SLC1A3 (0.38) | ACE | |
| SCHEMBL21246719 | 0.88 | ACE (0.39) | ACEPIN1MMP2MMP7MMP9 | |
| SCHEMBL19051537 | 0.86 | ACE (0.38) | ACEPIN1MMP2MMP7MMP9 | |
| SCHEMBL11133973 | 0.85 | TNF (0.37) | ACEPIN1 | |
| SCHEMBL17293240 | 0.84 | CTRB1 (0.37) | ACEMME | |
| SCHEMBL3916119 | 0.84 | CTRB1 (0.37) | ACEMME | |
| SCHEMBL749822 | 0.84 | CTRB1 (0.37) | ACEMME | |
| SCHEMBL3810013 | 0.84 | CTRB1 (0.37) | ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9044425-B2 | Method for topical treatment of eye disease and composition and device for said treatment | BABIZHAYEV MARK A (RU) | 2015-06-02 | — | — | US | disclosed |
| US-20100317586-A1 | METHOD FOR TOPICAL TREATMENT OF EYE DISEASE AND COMPOSITION AND DEVICE FOR SAID TREATMENT | BABIZHAYEV MARK A | 2010-12-16 | — | — | US | disclosed |
| US-7795203-B2 | topically applying an aqueous ophthalmic composition comprising N-acetylcarnosine, a N-acetylcarnosine derivative and a cellulose compound which increases intraocular absorption of N-acetylcarnosine; a hydrophilic hydrogel contact lens and an ocular polymer insert for topical application | BABIZHAYEV MARK A | 2010-09-14 | — | — | US | disclosed |
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | disclosed |
| EP-2144893-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008137816-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1551399-A1 | METHOD FOR TOPICAL TREATMENT OF EYE DISEASE AND COMPOSITION AND DEVICE FOR SAID TREATMENT | BABIZHAYEV, Mark A. (RU) | 2005-07-13 | — | — | EP | disclosed |
| US-20040192647-A1 | topically applying an aqueous ophthalmic composition comprising N-acetylcarnosine, a N-acetylcarnosine derivative and a cellulose compound which increases intraocular absorption of N-acetylcarnosine; a hydrophilic hydrogel contact lens and an ocular polymer insert for topical application | BABIZHAYEV MARK A (RU) | 2004-09-30 | — | — | US | disclosed |
| WO-2004028536-A1 | METHOD FOR TOPICAL TREATMENT OF EYE DISEASE AND COMPOSITION AND DEVICE FOR SAID TREATMENT | BABIZHAYEV MARK A (RU) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317586-A1 | METHOD FOR TOPICAL TREATMENT OF EYE DISEASE AND COMPOSITION AND DEVICE FOR SAID TREATMENT | NAT1, NISCH, UACA | ACE 148/4885PIN1 2616/4885MMP2 518/4885 |
| US-20040192647-A1 | topically applying an aqueous ophthalmic composition comprising N-acetylcarnosine, a N-acetylcarnosine derivative and a cellulose compound which increases intraocular absorption of N-acetylcarnosine; a hydrophilic hydrogel contact lens and an ocular polymer insert for topical application | NAT1, B3GNT2, UACA | ACE 401/4885PIN1 2339/4885MMP2 712/4885 |
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP13, MMP2, MMP12 | ACE 382/4885PIN1 2818/4885MMP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.